Abstract: Drug package inserts are a crucial foundation for clinical medication practices and serve as the legal basis for guiding rational drug use and ensuring patient safety and efficacy. As rare disease treatments evolve, current package inserts often need to meet the clinical requirements for treating such conditions, frequently resulting in off-label drug use. This consensus is derived from discussions between Guangdong Pharmaceutical Association Hematologic Rare Diseases Group experts. The consensus aims to provide a framework and reference for the clinical application of off-label drug use in treating rare hematologic diseases.
Introduction
In the field of rare diseases, clinical reality often moves faster than regulatory documentation. Drug package inserts—the legal and clinical "gold standard" for medication use—frequently lag years behind the latest research. For rare hematologic conditions, where patient populations are small and clinical trials are difficult to conduct, many life-saving treatments are technically "off-label."
In China, while the 2021 "Law on Doctors" permits off-label use under special circumstances with informed consent, there has been a historical lack of standardized, national guidance. This creates a "gray zone" that can lead to inconsistent care, safety risks, or legal vulnerabilities for healthcare providers. This 2024 expert consensus provides a standardized, evidence-based roadmap to bridge the critical gap between outdated drug package inserts and the urgent clinical needs of patients with "orphan" diseases.
Methodology and Evidence Standards
The consensus was developed using a Nominal Group Technique, involving a panel of 26 experts across hematology, clinical pharmacy, and pharmaceutical administration. The development process adhered to rigorous international standards, including the WHO Handbook for Guideline Development (2nd edition) and the RIGHT Statement for reporting practice guidelines.
The team utilized the Thomson Micromedex classification system to grade the efficacy, recommendation level, and evidence strength for each drug. When Micromedex data was unavailable—a common occurrence in rare disease research—the authors performed a comprehensive review of international and Chinese guidelines, as well as randomized controlled trials (RCTs) published in first-quartile (Q1) SCI journals. This multi-disciplinary approach ensures that off-label use moves from anecdotal practice to a structured, evidence-based framework.
Key Insights: Repurposing and Standardization
A central insight of this consensus is the continued dominance of repurposed existing drugs in the treatment of rare hematologic diseases in China. While gene therapies and immunotherapies are advancing, the clinical backbone remains the "old drug, new trick" approach.
By providing specific "Specific Usage" and "Evidence Level" parameters, the consensus serves as a safety shield for both patients and clinicians. It specifically addresses the "Micromedex Gap" by synthesizing high-quality Chinese and international clinical trial data for treatments not yet listed in standard pharmaceutical databases. Furthermore, it emphasizes that off-label use requires a pharmaceutical supervision framework involving pharmacists and hospital management, rather than being a solitary clinical decision.
Clinical Recommendations and Results
The consensus provides detailed evidence tables for ten major rare blood disorders, including Castleman’s disease, Erdheim-Chester disease (ECD), Fanconi anemia, and POEMS syndrome.
Castleman’s Disease
For Castleman’s disease, the consensus recommends several off-label options depending on the subtype (Unicentric vs. Multicentric) and the availability of primary therapies. Notable recommendations include Tocilizumab and Rituximab, particularly when first-line IL-6 inhibitors are unavailable or the patient is unresponsive to initial monoclonal antibody therapy.
Other Rare Hematologic Conditions
- Erdheim-Chester Disease (ECD): Vemurafenib is highlighted for patients with the BRAF V600 mutation, supported by FDA approval and international consensus guidelines.
- Sickle Cell Anemia: Hydroxyurea and L-glutamine are codified as standard off-label options within the Chinese clinical context.
- POEMS Syndrome: Detailed protocols for Lenalidomide and Thalidomide (combined with dexamethasone) are provided, carrying "Effectiveness Class IIa" ratings.
Limitations and Future Outlook
The authors acknowledge that rare disease treatment is a "moving target." As therapies evolve rapidly, even a 2024 edition will require frequent updates to incorporate emerging gene therapies and bispecific antibodies. Additionally, for the rarest conditions, the evidence level often remains Category C or "Not listed" due to the inherent difficulty of running large-scale RCTs.
Future work will focus on expanding the directory of diseases and incorporating real-world evidence (RWE) from Chinese clinical practice to further refine these recommendations and ensure they remain integrated into institutional ethical review systems.
Summary updated